Analysis of Chromium (III)Picolinate in Capsule dosage form
by using Stability indicating HPTLC Method
Chromium (III) picolinate is used as a nutritional supplement and has been valuable effects on carbohydrate and lipid metabolism alleviating symptoms associated with diabetes. A chromium supplement produces beneficial results in reducing insulin sulfonylurea or metformin requirements. Hence, stability indicating HPTLC method was developed for estimation of Chromium picolinate in capsule formulation. The development of HPTLC method optimization on precoated silica gel 60 F254 aluminium plates of 20 cm x 20 cm, 250μm thickness. The mobile phase used was methanol: ethyl acetate6:4 (v/v). The densitometry detection was done at 264 nm. Also, the forced degradation studies were performed and method was validated with as per ICH guidelines. The Rf value obtained was 0.39 ±0.05.Linearity data for the calibration curve gave a good linear relationship over the concentration range of 100-600ng/spot for Chromium picolinate (correlation coefficient R2 =0.9997). The percent recovery of Chromium picolinate in marketed formulation was found in the range of 99.56%.Force degradation and validation of method was done as per ICH guidelines and the results are within the compliance limit.The developed HPTLC method gave good results for force degradation studies show that the method is stability indicating. Thus, this method can be used for routine analysis of Chromium picolinate and can be use for its future usage